ANAPTYSBIO INC (ANAB)
Health Care · Clinical-stage immunology biotechnology / royalty-stage drug development · NASDAQ
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own clinical-stage pipeline for autoimmune and inflammatory diseases.
What ANAPTYSBIO INC does
AnaptysBio is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. Prior to a separation completed in April 2026, the company held a diversified pipeline including rosnilimab (for rheumatoid arthritis), ANB033 (for celiac disease and eosinophilic esophagitis), and ANB101 (BDCA2 modulator). Following the separation, the company now focuses on managing financial collaborations with GSK (for the approved immuno-oncology drug Jemperli/dostarlimab) and Vanda Pharmaceuticals (for imsidolimab), generating revenue primarily through milestone payments and royalties.
Themes: Immunology therapeutics, Autoimmune and inflammatory disease treatment, PD-1 antagonists / immuno-oncology, Royalty-based collaboration models, Rheumatoid arthritis, Endometrial cancer, Psoriasis, Clinical-stage development
Fundamentals
- Price$57.74 as of 2026-08-21 close
- Market cap$1.7B as of 2026-08-21
- 1-year return+325.4% 2025-08-21 close $13.57 → 2026-08-21 close $57.74
- P/En/a negative earnings
- Net margin-11.5% as of 2026-08-24
- ROE-13.1% as of 2026-08-24
- Debt / equity20.69 as of 2026-08-24
- Revenue growth (YoY)+107.7% as of 2026-08-24
- Revenue CAGR (3y)+183.6% SEC XBRL
- Beta0.87 as of 2026-08-24
- Last reported earnings2026-05-12 SEC EDGAR Form 8-K (Item 2.02)
How ANAB compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ANAPTYSBIO INC looks technically
ANAPTYSBIO INC (ANAB) is trading 30.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 284 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 5 trading days ago. It is 20.2% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move.
Trend
7
| Distance from the 200-day | it is trading 30.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +30.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $58.35 | $58.35 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $44.34 | $44.34 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 31 calendar days ago — the swings before that are what the structure reading is measured on | 31 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 284 trading days ago — a "golden cross", a bullish long-term signal | 284 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($53.41 to $60.31) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 62.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $72.36 | $72.36 |
|---|---|---|
| From the 52-week high | it is 20.2% below its 52-week high (its highest price of the past year) | -20.2% |
| Above the 52-week low | it is 406.3% above its 52-week low (its lowest price of the past year) | +406.3% |
| Below the 52-week high | it is 20.2% below its highest point of the past year | 20.2% |
| Since a 20-day breakout | it made a new 20-day high about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 25 trading days ago | 25 sessions |
| All-time high | its highest closing price on record is $89.33 (set on 2018-02-20) | $89.33 |
| Given back of the 52-week move | over the past year its closes ranged ($12.93 to $69.81), and it has given back roughly a quarter of its rise from last year’s low — 21% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $32.84 to $34.66. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 21.2% |
| From the all-time high | it is 35.4% below its all-time high | -35.4% |
| Nearest price level | it is trading 13.2% above a support level at $50.09 — a price it turned at three times since 2026-06-08, most recently on 2026-07-29. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -13.2% |
| All-time low | its lowest closing price on record is $6.67 (set on 2019-11-08) | $6.67 |
| Above the all-time low | it is 766.1% above its all-time low | +766.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.93 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.93 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $51.45 and $60.41 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $51.45 – $55.93 – $60.41 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 4.6 daily ranges above its 200-day average price (30.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.55× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 3.0% below the previous close 27 sessions ago and has not traded back through the level it left behind at 62.51 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.0% |
| Gap filled | a 2.2% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.1 percentage points (the stock gained 7.4% while the market gained 2.3%) | +5.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 7.5 percentage points (the stock lost 4.4% while the market gained 3.1%) | -7.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 48.8 percentage points (the stock gained 59.8% while the market gained 11.1%) | +48.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 304.9 percentage points (the stock gained 325.4% while the market gained 20.5%) | +304.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.4% of the share price, which is taken to mean a barrier that gives way easily. | -5.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 21% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $47.66 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +21.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-05-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $58.35 — a volume-weighted average of daily closes over 68 sessions, not a true tick-by-tick VWAP. | -1.1% |
Price levels it has turned at before
ANAB last closed at $57.74 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $50.09 | Support | 13.2% below the last close | turned there three times · 2026-06-08 to 2026-07-29 |
| $38.46 | Support | 33.4% below the last close | turned there twice · 2026-02-13 to 2026-02-24 |
| $34.93 | Support | 39.5% below the last close | turned there three times · 2025-12-29 to 2026-03-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$87.09 range $70.00 – $140.00; median $81.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ANAB
- Consensus EPS estimate$0.1415 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Product candidates in development may fail or experience delays that adversely affect commercial viability; clinical trial results may not be representative of future trial outcomes.","The company has limited operating revenue, a history of operational losses, and no products approved for commercial sale; additional capital will be required to finance operations and complete development programs.","Dependence on GSK collaboration for Jemperli revenue and milestone recognition; loss or failure of this collaboration could materially adversely affect the business."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ANAB — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ANAB as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,478,579
- Reported value $192,921,994
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ANAB had 5,401,866 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ANAB had 18.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.21 days to cover at the same settlement.
- Reported short interest (shares) 5,401,866
- Short interest (% of shares outstanding) 18.6%
- Prior settlement (shares) 4,999,494
- Reported change 8.05%
- Days to cover (reported) 7.21
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK) — immuno-oncology competitive landscape
- Bristol Myers Squibb (BMY) — immunology and cell therapy
- Regeneron Pharmaceuticals (REGN) — immunology therapeutics
- Gilead Sciences (GILD) — autoimmune disease treatment
- AbbVie (ABBV) — rheumatoid arthritis and autoimmune treatments
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ANAB vs…
Frequently asked questions
What does ANAPTYSBIO INC (ANAB) do?
AnaptysBio is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. Prior to a separation completed in April 2026, the company held a diversified pipeline including rosnilimab (for rheumatoid arthritis), ANB033 (for celiac disease and eosinophilic esophagitis), and ANB101 (BDCA2 modulator).
What sector is ANAPTYSBIO INC (ANAB) in?
ANAPTYSBIO INC (ANAB) is classified in the Health Care sector. Its industry is Clinical-stage immunology biotechnology / royalty-stage drug development. It trades on NASDAQ.
Who are ANAPTYSBIO INC's (ANAB) competitors?
Notable peers of ANAPTYSBIO INC (ANAB) include Merck (MRK) — immuno-oncology competitive landscape, Bristol Myers Squibb (BMY) — immunology and cell therapy, Regeneron Pharmaceuticals (REGN) — immunology therapeutics, Gilead Sciences (GILD) — autoimmune disease treatment and AbbVie (ABBV) — rheumatoid arthritis and autoimmune treatments. This peer set is informational only — not financial advice.
Is ANAPTYSBIO INC (ANAB) overbought or oversold right now?
ANAPTYSBIO INC (ANAB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ANAB come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.